EVGN
Evogene Ltd.NASDAQHealthcare$0.78-0.41%ClosedMarket Cap: $6.8M
As of 2026-04-06
Valuation
P/E (TTM)
—
PEG
—
P/B
-87.16
P/S
1.81
EV/EBITDA
0.32
DCF Value
$-3.74
FCF Yield
-201.9%
Div Yield
0.0%
Margins & Returns
Gross Margin
35.4%
Operating Margin
-377.0%
Net Margin
-214.6%
ROE
553.2%
ROA
-42.3%
ROIC
-82.6%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $314.0K | -16.9% | $-5.0M | $-5.3M | $-0.61 | — |
| FY 2025 | $3.9M | 20.6% | $-14.0M | $-8.5M | $-1.08 | — |
| Q3 2025 | $312.0K | -40.4% | $-2.7M | $3.9M | $0.44 | — |
| Q2 2025 | $884.0K | 51.8% | $-3.1M | $-4.5M | $-0.62 | — |
| Q1 2025 | $2.4M | 10.3% | $-4.3M | $-2.6M | $-0.38 | — |
| Q4 2024 | $1.6M | 16.3% | $-4.6M | $427.0K | $0.06 | — |
| FY 2024 | $8.5M | 39.8% | $-21.7M | $-16.5M | $-2.89 | — |
| Q3 2024 | $1.7M | 28.1% | $-5.9M | $-7.6M | $-1.31 | — |
| Q2 2024 | $605.0K | -10.1% | $-4.6M | $-5.4M | $-1.06 | — |
| Q1 2024 | $4.2M | 76.6% | $-3.6M | $-3.9M | $-0.76 | — |
| Q4 2023 | $578.0K | -83.6% | $-7.6M | $-6.6M | $-1.30 | — |
| FY 2023 | $5.6M | 24.8% | $-26.4M | $-23.9M | $-5.23 | — |